DRMA

Dermata Therapeutics (DRMA)

About Dermata Therapeutics (DRMA)

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Details

Daily high

$1.15

Daily low

$1.06

Price at open

$1.07

52 Week High

$13.35

52 Week Low

$1.00

Market cap

2.2M

Dividend yield

0.00%

Volume

159,039

Avg. volume

600,671

P/E ratio

-.05

Dermata Therapeutics News